Natural Psilocybin (PEX010)
Adjustment Disorder due to a recent diagnosis of incurable cancer
Phase IIbActive
Key Facts
Indication
Adjustment Disorder due to a recent diagnosis of incurable cancer
Phase
Phase IIb
Status
Active
Company
About Psyence Biomedical
Psyence Biomedical's mission is to develop and commercialize natural psilocybin-based therapies for psychological trauma, with a primary focus on adjustment disorder due to incurable cancer. Its key achievement is the advancement of its lead candidate into a Phase IIb clinical trial under a Health Canada-authorized Clinical Trial Application, supported by a proprietary GMP cultivation and production facility. The company's strategy hinges on the clinical validation of its natural psilocybin, vertical integration for supply chain control, and targeting a high-unmet-need indication to establish a specialized therapeutic niche.
View full company profile